Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion. As previously announced, this study has received all regulatory approvals to initiate in Australia and will be conducted at CMAX Clinical Research, Skye's contract clinical trial unit in Adelaide, Australia.

The primary endpoints for this randomized, double-masked, placebo-controlled study are to assess safety and tolerability of the drug in healthy volunteers. The secondary endpoint is to assess pharmacokinetics. The study will also measure changes to intraocular pressure …

Full story available on Benzinga.com